Advertisement

Search Results

Advertisement



Your search for The matches 22878 pages

Showing 1 - 50


New Guidelines on Cervical Cancer Screening

This week, we'll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we'll discuss the FDA's approval of a triplet therapy for advanced melanoma. Lastly, we'll hear a summary of a panel discussion on telehealth for patients with...

covid-19

Jessica Y. Islam, PhD, MPH, on COVID-19 Preventive Behaviors Among Cancer Survivors

Jessica Y. Islam, PhD, MPH, of the UNC Lineberger Comprehensive Cancer Center, discusses findings from the COVID-19 Impact Survey, which showed that cancer survivors are adhering to many of the recommended COVID-19 preventive behaviors, such as wearing masks and social distancing.

covid-19

Nancy E. Davidson, MD, on Bringing Patients With Cancer Back to the Clinic During the COVID-19 Pandemic

Nancy E. Davidson, MD, of Fred Hutchinson Cancer Research Center, talks about a panel she moderated in which speakers discussed the importance of communicating with patients to ease their concerns about cancer care during the COVID-19 pandemic, allocating protective gear for the most vulnerable...

breast cancer
covid-19

Increased Time to Breast Cancer Surgery May Not Impact Overall Survival for Patients With Early-Stage Disease

A new study published by Minami et al in the Journal of the American College of Surgeons found that longer time from diagnosis to surgical treatment did not lower overall survival in women with early-stage breast cancer. These findings may be reassuring for women with early-stage breast cancer who...

leukemia

Refinement of European LeukemiaNet Classification Recommendations for Younger Adults With AML

Findings from a study published by Eisfeld et al in the journal Leukemia could refine an important set of prognostic and treatment recommendations for younger adult patients with acute myeloid leukemia (AML). The retrospective study evaluated the molecular characteristics and outcomes of 863...

gynecologic cancers
immunotherapy

Avelumab for Patients With Gestational Trophoblastic Tumors Resistant to Single-Agent Chemotherapy

In the French phase II TROPHIMMUN trial reported in the Journal of Clinical Oncology, Benoit You, MD, PhD, and colleagues found that avelumab normalized human chorionic gonadotropin (hCG) levels in approximately half of women with gestational trophoblastic tumors resistant to single-agent...

breast cancer

Association of Pathologic Complete Response With 3-Year Outcomes in I-SPY 2 Trial of Neoadjuvant Therapy for Stage II or III Breast Cancer

In a 3-year follow-up analysis of the phase II I-SPY 2 trial reported in JAMA Oncology, researchers in the I-SPY 2 Trial Consortium found that pathologic complete response was associated with improved event-free and distant recurrence–free survival—irrespective of molecular subtype or neoadjuvant...

hepatobiliary cancer
immunotherapy

First-Line Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

In a phase Ib trial reported in the Journal of Clinical Oncology, Richard S. Finn, MD, and colleagues found that the combination of lenvatinib and pembrolizumab produced durable responses in patients with unresectable hepatocellular carcinoma who had received no prior systemic chemotherapy. As...

kidney cancer
lung cancer
myelodysplastic syndromes
solid tumors
skin cancer
lymphoma
pancreatic cancer
breast cancer
immunotherapy

FDA Pipeline: Designations in Kidney and Lung Cancers, Myelodysplastic Syndromes, and More

Over the past few weeks, the U.S. Food and Drug Administration (FDA) has issued designations and accepted applications for novel agents, as well as approved companion diagnostics. We summarize these regulatory movements below. Breakthrough Therapy Designation for MK-6482 in von Hippel-Lindau...

hepatobiliary cancer
immunotherapy

Combination Immunotherapy in Advanced Biliary Tract Cancers

In a subgroup analysis of an Australian phase II trial reported in JAMA Oncology, Klein et al found that the combination of nivolumab and ipilimumab was active in patients with advanced biliary tract cancers. Study Details The phase II trial is enrolling patients with advanced rare cancers. The...

lymphoma
immunotherapy

Anti-CD30 CAR T-Cell Therapy for Patients With Relapsed or Refractory Hodgkin Lymphoma

In a pooled analysis of two parallel single-center phase I/II studies reported in the Journal of Clinical Oncology, Ramos et al found that anti-CD30 chimeric antigen receptor (CAR) T-cell therapy produced responses in a high proportion of patients with relapsed or refractory Hodgkin lymphoma. As...

pancreatic cancer

Addition of Pegvorhyaluronidase Alfa to Nab-paclitaxel and Gemcitabine in Hyaluronan-High Metastatic Pancreatic Cancer

In the phase III HALO 109-301 trial reported in the Journal of Clinical Oncology, Eric Van Cutsem, MD, PhD, and colleagues found that the addition of pegvorhyaluronidase alfa (PEGPH20) to nab-paclitaxel plus gemcitabine (AG) did not improve overall survival or progression-free survival in patients...

multiple myeloma
immunotherapy

FDA Grants Accelerated Approval to Belantamab Mafodotin-blmf for Pretreated Patients With Relapsed or Refractory Multiple Myeloma

On August 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to belantamab mafodotin-blmf (Blenrep), an anti-B-cell maturation antigen antibody-drug conjugate, for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies,...

issues in oncology

Antoni Ribas, MD, PhD, on Turning Science Into Life-Saving Care

Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, summarizes the opening plenary session that addressed epigenetics and early detection, how the aging microenvironment governs response to therapy, AI-driven precision medicine, reprogramming...

covid-19

Antoni Ribas, MD, PhD, on AACR Virtual Meeting: COVID-19 and Cancer Highlights

Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, and the President of AACR, discusses this special conference that focused on emerging data related to COVID-19 and cancer, ways in which the coronavirus pandemic has altered treatment of...

covid-19

Catherine H. Marshall, MD, MPH, on Promoting Recovery From COVID-19 Infection With Endocrine Therapy

Catherine H. Marshall, MD, MPH, of Johns Hopkins Hospital, discusses phase II trial results on bicalutamide, an oral antiandrogen used to treat prostate cancer. Bicalutamide may be helpful in downregulating the TMPRSS2 and ACE proteins needed for the SARS-CoV-2 virus; upregulating estradiol to help ...

covid-19

Karen E. Knudsen, MBA, PhD, on the Challenges of Using Telehealth in Cancer Care

Karen E. Knudsen, MBA, PhD, of the Sidney Kimmel Cancer Center at Jefferson Health, summarizes a panel she moderated on telehealth, which included discussion of usage in urban vs rural populations, preventing the technology from becoming a new source of disparities in cancer care, and uncertainties ...

covid-19

Arthur L. Caplan, PhD, on Ethics, Cancer, and COVID-19

Arthur L. Caplan, PhD, of New York University–Langone Health, discusses the areas in cancer care that need to be improved in the midst of the coronavirus pandemic, including a better definition of essential medical services based on the potential to save lives, offer good quality of life, and ease...

supportive care
immunotherapy

ASCO Guideline Supports Continued Use of Dexamethasone for Patients Receiving Checkpoint Inhibitors and Emetogenic Chemotherapy

The ASCO guideline on the use of antiemetics has been updated to include new anticancer agents, antiemetics, and regimens.1 The guideline also addresses a growing concern among some oncologists that corticosteroids and their immunosuppressive abilities could potentially compromise the efficacy of...

survivorship

Severe Hearing Impairment Associated With Neurocognitive Deficits in Childhood Cancer Survivors

Findings from a report published by Bass et al in JAMA Oncology show that childhood cancer survivors with severe hearing loss are at a significant increased risk for neurocognitive deficits, independent of what type of therapy they receive. This study is the first to objectively measure hearing and ...

hematologic malignancies
breast cancer

Risk of Breast Cancer After Total-Body Irradiation and Blood or Marrow Transplantation for Hematologic Malignancies

In an analysis from the Blood or Marrow Transplantation Survivor Study reported in the Journal of Clinical Oncology, McDonald et al found that total-body irradiation in women undergoing autologous or allogeneic blood or marrow transplantation for hematologic malignancies was associated with an...

colorectal cancer

Second-Look Surgery Plus HIPEC vs Surveillance for Patients at High Risk for Colorectal Peritoneal Metastases

In a French phase III trial (PROPHYLOCHIP–PRODIGE 15) reported in The Lancet Oncology, Goéré et al found that second-look surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) did not improve disease-free survival vs standard surveillance in patients at high risk of developing colorectal...

cns cancers

Outcomes With Adjuvant Postradiation Chemotherapy vs Radiotherapy in High-Risk, Low-Grade Glioma

In a post hoc analysis from the phase III NRG Oncology/RTOG 9802 trial reported in the Journal of Clinical Oncology, Bell et al found that postradiation chemotherapy was associated with a better outcome vs radiotherapy alone in patients with IDH-mutant, high-risk, low-grade glioma, irrespective of...

immunotherapy

Ralph R. Weichselbaum, MD, on Radiotherapy and Immunotherapy in Oligometastatic Disease

Ralph R. Weichselbaum, MD, of the University of Chicago Cancer Research Center, explores the question of whether radiotherapy is the principal curative treatment with immunotherapy or activates immunotherapy. He also discussed how to improve the interaction of these treatments, perhaps with...

lung cancer

Ramaswamy Govindan, MD, on Differences Among Male and Female Patients With Lung Cancer

Ramaswamy Govindan, MD, of Washington University School of Medicine, discusses sex differences in lung cancer, including variations in treatment response, and the state of research in the field (Session ED20).

immunotherapy

Silvia Formenti, MD, on Testing Radiation and Immune Checkpoint Blockade in Different Tumor Settings

Silvia Formenti, MD, of Weill Cornell Medical College, discusses her continuing work, and the promising results emerging, in combining radiotherapy with immunotherapy to boost abscopal response rates. This combination therapy extends the use of radiotherapy to promote antitumor T-cell responses for ...

myelodysplastic syndromes
genomics/genetics

Role of TP53 Mutations on Disease Severity in Myelodysplastic Syndromes

Considered the “guardian of the genome,” TP53 is the most commonly mutated gene in patients with cancer. TP53's normal function is to detect DNA damage and prevent cells from passing this damage on to daughter cells. When TP53 is mutated, the protein made from this gene, called p53, can no longer...

ASH Annual Meeting Announced as an All-Virtual Event

The American Society of Hematology (ASH) announced its decision not to hold the 62nd ASH Annual Meeting in San Diego as planned given the continuing threat of the COVID-19 pandemic. The meeting will be offered as a virtual experience from December 5–8, 2020. The Society commented, “While there is...

covid-19

Nationwide Trends Show Fewer Patients With Cancer in the United States Seeking Care Since Start of the COVID-19 Pandemic

Research published by London et al in JCO Clinical Cancer Informatics found significant decreases nationwide in the number of patients seen for cancer-related care as the COVID-19 pandemic progressed during the first few months of 2020. The most significant decline was seen in encounters related to ...

prostate cancer

Does Adding Neoadjuvant Chemohormonal Therapy to Surgery in Patients With Localized High-Risk Prostate Cancer Improve Biochemical Progression-Free Survival?

As reported in the Journal of Clinical Oncology by Eastham et al, the phase III CALGB 90203/Alliance trial has shown no improvement in 3-year biochemical progression-free survival (BPFS) with the addition of neoadjuvant chemohormonal therapy to radical prostatectomy in patients with localized...

leukemia
survivorship

Late Morbidity and Mortality in Survivors of Childhood ALL Receiving Contemporary Risk-Stratified Therapy

In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Dixon et al found that 5-year survivors of childhood acute lymphoblastic leukemia (ALL) diagnosed and treated with risk-stratified therapy in the 1990s had reduced morbidity and health-related late ...

lung cancer

Pyrotinib for Pretreated Patients With HER2-Mutated Advanced NSCLC

In a Chinese phase II trial reported in the Journal of Clinical Oncology, Zhou et al found that pyrotinib produced durable responses in patients with HER2-mutated advanced non–small cell lung cancer (NSCLC) who had received prior platinum-based chemotherapy.   Study Details The multicenter study...

lymphoma

FDA Approves Tafasitamab-cxix Combined With Lenalidomide to Treat Adults With Relapsed/Refractory DLBCL

On July 31, the U.S. Food and Drug Administration (FDA) approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL arising from low-grade...

palliative care

Overcoming the Challenges of Improving Psychosocial Care for Patients With Cancer

Although the United States spends billions of dollars each year on cancer research, very little of that funding is dedicated to mental health research in patients with cancer, despite the fact that cancer survivors have a six-time higher risk for psychological disability than people without...

prostate cancer

Pan-BET Bromodomain Inhibitor Plus Enzalutamide in Advanced Prostate Cancer

A new multi-institution, dose-determining clinical trial of a compound for patients with metastatic, castration-resistant prostate cancer showed the combination “demonstrated acceptable tolerability and potential efficacy,” reported Aggarwal et al in Clinical Cancer Research. The phase Ib/IIa study ...

covid-19

ESMO Issues Consensus on the Management of Patients With Cancer During the COVID-19 Pandemic

A European Society for Medical Oncology (ESMO) interdisciplinary expert consensus paper on how to manage patients with cancer during the COVID-19 pandemic was published by Giuseppe Curigliano, MD, PhD, and colleagues in Annals of Oncology. The guidance encourages medical oncologists worldwide not...

breast cancer

NALA Trial: Neratinib/Capecitabine vs Lapatinib/Capecitabine for Pretreated Patients With HER2-Positive Metastatic Breast Cancer

As reported in the Journal of Clinical Oncology by Cristina Saura, MD, and colleagues, the phase III NALA trial has shown significantly prolonged progression-free survival with neratinib/capecitabine vs lapatinib/capecitabine in patients with HER2-positive metastatic breast cancer who had received...

leukemia

Sorafenib Maintenance After Allogeneic HCT in Patients With FLT3-ITD–Positive AML

In the German-Austrian phase II SORMAIN trial reported in the Journal of Clinical Oncology, Burchert et al found that maintenance treatment with sorafenib vs placebo was associated with significantly prolonged relapse-free survival after allogeneic hematopoietic stem cell transplantation (HCT) in...

Comparison of Two Combination Treatments in Localized Pancreatic Cancer

This week, we’ll discuss a study that compared two combination treatments for previously untreated patients with localized pancreatic cancer. Then, we’ll explore whether a longer-established diagnosis of cancer is associated with higher risk of severe COVID-19 infection or death from the virus....

skin cancer
immunotherapy

FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma

On July 30, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor atezolizumab (Tecentriq) plus the MEK inhibitor cobimetinib (Cotellic) and the selective BRAF kinase inhibitor vemurafenib (Zelboraf) for the treatment of patients with advanced BRAF V600 mutation–positive...

supportive care
symptom management

Updated ASCO Guideline Revisits Evidence on Prevention and Treatment of Chemotherapy-Induced Neuropathy

Peripheral neuropathy is one of the most prominent chronic side effects of chemotherapy and can linger for years, causing discomfort as well as impaired functionality and quality of life. Yet oncologists have struggled to identify definitive treatment and prevention strategies. In an effort to help ...

sarcoma

Addition of Pazopanib to Preoperative Chemoradiotherapy in Children and Adults With Soft-Tissue Sarcoma

In an interim analysis of a joint Children’s Oncology Group and NRG Oncology phase II trial (ARST1321) reported in The Lancet Oncology, Aaron R. Weiss, DO, and colleagues found that the addition of pazopanib to preoperative chemoradiotherapy significantly increased the rate of pathologic...

colorectal cancer

Xavier Llor, MD, PhD, on Colorectal Cancer: Why Are More Younger People Being Affected?

Xavier Llor, MD, PhD, of Yale University School of Medicine, discusses the steep rise of early-onset colorectal cancer over the past 15 years, which cannot be explained by genetic predisposition but may be prompted by environmental factors (Session ED35).

multiple myeloma
genomics/genetics

Analysis of Deep Whole-Genome Sequencing in Patients With Multiple Myeloma Identifies Superior Outcome Subgroup

In a study of genome-wide somatic alterations in multiple myeloma reported in the Journal of Clinical Oncology, Samur et al identified a subgroup of patients with superior outcomes who are not adequately identified by traditional risk markers. The study involved analysis of deep whole-genome...

colorectal cancer

Does Periodontal Disease Increase the Risk of Colorectal Cancer?

Periodontal disease was associated with an increased risk of two precursors of colorectal cancer, according to results of a study published by Lo et al in Cancer Prevention Research. “Periodontal disease is prevalent among adults, with periodontitis affecting more than 40% of the U.S. population,”...

gynecologic cancers

American Cancer Society Updates Guideline for Cervical Cancer Screening

An updated cervical cancer screening guideline from the American Cancer Society released today has called for less—and more simplified—screening. The guideline was published by Fontham et al in CA: A Cancer Journal for Clinicians. The updated guideline recommends that individuals with a cervix...

gastrointestinal cancer

First-Line S-1 Plus Leucovorin and Oxaliplatin vs S-1 Plus Cisplatin in Advanced Gastric Cancer

As reported in The Lancet Oncology by Kang et al, the Japanese-Korean phase III SOLAR trial showed that oral tegafur/gimeracil/oteracil, a combination known as S-1, plus leucovorin and oxaliplatin was associated with a modest but significant improvement in overall survival vs S-1 plus cisplatin in...

skin cancer
immunotherapy

Pembrolizumab in Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma

As reported in the Journal of Clinical Oncology by Grob et al, the first interim analysis of the phase II KEYNOTE-629 trial has shown that treatment with pembrolizumab resulted in durable responses in patients with recurrent or metastatic cutaneous squamous cell carcinoma. The study supported the...

covid-19

Top Scientists Share Early Research on Intersection of COVID-19 and Cancer Care at AACR Virtual Meeting

The American Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer took place from July 20 to 22, 2020, attracting top scientific minds from around the world to present preliminary research on the ever-evolving COVID-19 pandemic and its intersection with cancer care. In an...

issues in oncology

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based...

Advertisement

Advertisement



Advertisement